Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Regeneron Pharmaceuticals (NQ:REGN)

641.96 +6.13 (+0.96%)
Streaming Delayed Price Updated: 2:11 PM EDT, Mar 28, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 232,060
Open 638.01
Bid (Size) 640.63 (2)
Ask (Size) 642.19 (1)
Prev. Close 635.83
Today's Range 631.45 - 642.97
52wk Range 629.02 - 1,211.20
Shares Outstanding 91,779,465
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
$1000 Invested In This Stock 20 Years Ago Would Be Worth This Much Today
Via Benzinga
Sensei Biotherapeutics Reports Favorable Initial Clinical Activity Data For Solnerstotug In Resistant Tumors
Sensei Biotherapeutics' solnerstotug shows a 14% ORR in PD-(L)1 resistant tumors and remains well tolerated in early trial data from its Phase 1/2 study. 
Via Benzinga

Performance

YTD
-10.2%
-10.2%
1 Month
-11.3%
-11.3%
3 Month
-10.4%
-10.4%
6 Month
-38.3%
-38.3%
1 Year
-33.6%
-33.6%

More News

Read More
Dupixent® (dupilumab) Approved as the First-ever Biologic Medicine in Japan for Patients with Chronic Obstructive Pulmonary Disease (COPD)
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Merck's Biggest Moneymaker Could Get Even Bigger. But Will It Help Downtrodden Shares?
Via Investor's Business Daily
Exposures Product Safety
1 Dividend Stock Down 30% to Buy and Hold for the Next Decade
Via The Motley Fool
Why Pharma and Biotech Stocks Got Thrashed on Tuesday
Via The Motley Fool
What's going on in today's session: S&P500 movers
Via Chartmill
Regeneron to Report First Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on April 29, 2025
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Unity Biotechnology Unveils Mixed Data From Study For Diabetes-Related Blindness, Stock Falls
Via Benzinga
Opthea Phase 3 Trial Fails To Meet Primary Endpoint, Faces Financial Uncertainty
Via Benzinga
3 Reasons to Sell REGN and 1 Stock to Buy Instead
Via StockStory
Natera (NASDAQ:NTRA) Q4 Earnings: Leading The Immuno-Oncology Pack
Via StockStory
Topics Artificial Intelligence
Exposures Artificial Intelligence
Price Over Earnings Overview: Regeneron Pharmaceuticals
Via Benzinga
2 Large-Cap Stocks with Solid Fundamentals and 1 to Brush Off
Via StockStory
Friday's session: top gainers and losers in the S&P500 index
Via Chartmill
These S&P500 stocks are gapping in today's session
Via Chartmill
3 Stocks With Ironclad Balance Sheets for Long-Term Stability
Via MarketBeat
Topics Economy Supply Chain
Exposures Economy Supply Chain
What's going on in today's session: S&P500 gap up and gap down stocks
Via Chartmill
Regeneron Science Talent Search 2025 Awards More Than $1.8 Million to High School Seniors for Innovative Scientific Research on Classifying Objects in Space, Treating a Rare Muscle Disease and Solving a Long-Standing Math Problem
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Which S&P500 stocks are moving on Monday?
Via Chartmill
REGN DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Regeneron Pharmaceuticals, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important March 10 Deadline in Securities Class Action – REGN
From The Rosen Law Firm PA
Via GlobeNewswire
REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
Top S&P500 movers in Monday's session
Via Chartmill
Amgen And Kyowa Kirin's Rocatinlimab Reduces Eczema Severity In Phase 3 Study
Via Benzinga
REGN Deadline: Rosen Law Firm Urges Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights
From The Rosen Law Firm, P.A.
Via Business Wire

Frequently Asked Questions

Is Regeneron Pharmaceuticals publicly traded?
Yes, Regeneron Pharmaceuticals is publicly traded.
What exchange does Regeneron Pharmaceuticals trade on?
Regeneron Pharmaceuticals trades on the Nasdaq Stock Market
What is the ticker symbol for Regeneron Pharmaceuticals?
The ticker symbol for Regeneron Pharmaceuticals is REGN on the Nasdaq Stock Market
What is the current price of Regeneron Pharmaceuticals?
The current price of Regeneron Pharmaceuticals is 641.96
When was Regeneron Pharmaceuticals last traded?
The last trade of Regeneron Pharmaceuticals was at 03/28/25 02:11 PM ET
What is the market capitalization of Regeneron Pharmaceuticals?
The market capitalization of Regeneron Pharmaceuticals is 58.92B
How many shares of Regeneron Pharmaceuticals are outstanding?
Regeneron Pharmaceuticals has 59B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.